Comparative Pharmacology
Head-to-head clinical analysis: STALEVO 150 versus STALEVO 75.
Peer-Reviewed Evidence
Head-to-head clinical analysis: STALEVO 150 versus STALEVO 75.
STALEVO 150 vs STALEVO 75
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Stalevo 150 is a combination of carbidopa, levodopa, and entacapone. Levodopa is converted to dopamine in the brain, replenishing striatal dopamine levels. Carbidopa inhibits peripheral decarboxylation of levodopa, increasing its bioavailability. Entacapone is a selective and reversible inhibitor of catechol-O-methyltransferase (COMT), reducing peripheral metabolism of levodopa to 3-O-methyldopa.
STALEVO 75 is a combination product containing carbidopa, levodopa, and entacapone. Levodopa is the metabolic precursor of dopamine, which crosses the blood-brain barrier and is converted to dopamine in the brain, thereby ameliorating dopamine deficiency in Parkinson's disease. Carbidopa inhibits peripheral decarboxylation of levodopa, increasing levodopa availability to the brain. Entacapone is a selective and reversible inhibitor of catechol-O-methyltransferase (COMT), primarily in the periphery, which prolongs the plasma half-life of levodopa.
One tablet orally three times daily. Each tablet contains 150 mg levodopa, 37.5 mg carbidopa, and 200 mg entacapone.
Oral, 1 tablet (levodopa 75 mg, carbidopa 18.75 mg, entacapone 200 mg) taken 3 to 4 times daily. Maximum recommended dose: 10 tablets per day (levodopa 750 mg, carbidopa 187.5 mg, entacapone 2000 mg). Dose should be adjusted based on individual response and tolerability.
None Documented
None Documented
Levodopa (with carbidopa): ~1.5-2 hours. Carbidopa: ~1-2 hours. Entacapone: ~0.4-0.7 hours (short half-life; not primary determinant of dosing interval). Clinically, levodopa half-life determines dosing frequency for motor fluctuations.
Levodopa: 1.5-2 hours (alone). With carbidopa: 1.5 hours. Entacapone: 0.4-0.7 hours (elimination half-life). Clinical context: Entacapone prolongs levodopa half-life by ~30% via COMT inhibition.
Carbidopa and levodopa are primarily excreted renally. Levodopa: ~70-80% renal, with metabolites including 3-O-methyldopa. Carbidopa: ~50-70% renal, with ~30% fecal. Entacapone: ~90% fecal (mainly as metabolites), ~10% renal.
Carbidopa: 70% renal (metabolites), 30% fecal. Levodopa: 80% renal (metabolites), 20% fecal. Entacapone: 90% fecal, 10% renal.
Category C
Category C
Anti-Parkinson Agent
Anti-Parkinson Agent